NSE · Healthcare · Drug Manufacturers - General
| Document | Date |
|---|---|
| Annual report FY2026 SAI PARENTERALS LIMITED - ANNUAL REPORT 2025-26 SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Consolidated Revenue FY 2025-26: ₹381 Crore (vs | 2026-08-19 |
| Q1 FY27 earnings call SAI PARENTERALS LIMITED – Q1 FY'27 EARNINGS CALL SUMMARY HEADLINE NUMBERS • Consolidated total revenue: Rs. 182 crores (Q1 FY'27) vs Rs. 201 crores | 2026-08-18 |
| Investor presentation · Q1 FY27 SAI PARENTERALS LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Revenue Composition: CDMO 63% of net revenue (355.6% CAGR over FY23–FY26); Brande | 2026-08-12 |
| Quarterly results · Q1 FY27 SAI PARENTERALS LIMITED - BOARD MEETING SUMMARY DOCUMENT DATE: 11 AUGUST 2026 | QUARTER ENDED: 30 JUNE 2026 --- HEADLINE NUMBERS • Standalone Q1 F | 2026-08-11 |
| Q4 FY26 earnings call SAI PARENTERALS LIMITED – EARNINGS CALL SUMMARY Q4 & FY 2026 | May 27, 2026 --- HEADLINE NUMBERS • FY 2026 Consolidated Revenue: INR 381 crores (13 | 2026-05-29 |
| Investor presentation · Q4 FY26 SAI PARENTERALS LIMITED – INVESTOR SUMMARY --- HEADLINE NUMBERS • Q4FY26 Consolidated Revenue: ₹198 crore • FY26 Consolidated Revenue: ₹381 crore • | 2026-05-26 |
| Quarterly results · Q4 FY26 SAI PARENTERALS LIMITED - FINANCIAL SUMMARY HEADLINE NUMBERS • Q4 FY26 Revenue: ₹197.93 crores (+166.65% QoQ vs ₹74.23 crores in Q4 FY25) • Q4 FY26 | 2026-05-23 |
Readable in the app.
| Announcement | Date |
|---|---|
| Received orders/contracts for pharmaceutical products Sai Parenterals Limited's subsidiary, Noumed Pharmaceuticals Pty Limited, has renewed and expanded its long-term over-the-counter (OTC) medicines supply agreement with a leading Australian p | 2026-08-25 |
| Received new orders/contracts Sai Parenterals Limited's subsidiary, Noumed Pharmaceuticals Pty Limited, has secured an exclusive over-the-counter (OTC) medicine supply agreement with Australia's leading pharmacy network. | 2026-07-01 |
| Received new orders/contracts Sai Parenterals Limited has received a significant purchase order worth USD 11 million (Rs. 104.50 crores) from PILL CORP, Bulacan, Philippines for supplying anti-TB (tuberculosis) products. | 2026-05-28 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sai Parenteral's Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.